Bladder cancer
Immunotherapy and antibody-drug conjugates: handling AEs and special populations
Lernziel: Get familiar with the current indications of immunotherapy and antibody-drug conjugates for metastatic urothelial carcinoma (UCa). Learn to identify patient characteristics that impact the appropriateness of immunotherapy and the antibody-drug conjugate enfortumab vedotin. Gain knowledge on how to handle adverse events (AEs).
Fachgebiet: Medical oncology, urology, clinical oncology, (radiation oncology)
Zielpublikum: CME (basic, intermediate), Residents (senior)
Letzte Aktualisierung: July 2023
Hintergrund:
Regulatory approval status of drugs for metastatic UCa (status: 31 May 2023)
CPS: combined positive score